- Poster presentation
- Open Access
HCV genotypes distribution in the Nizhny Novgorod area HIV-positive population
© Minaeva et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Viral Hepatitis
- Sustained Virologic Response
- Virologic Response
- Polymerase Chain Reaction Method
- Chronic Viral Hepatitis
The number of people infected due to intravenous drug use remains at a level of 50% so far, despite the HIV sexual transmission rate increasing. Chronic hepatitis C (HCV) infection is currently one of the most clinically relevant co-morbidities (>80%) in the population of HIV-positive drug-users. Due to the wide use of HAART and prevention of opportunistic diseases, life expectancy of HIV-infected individuals has increased and chronic viral hepatitis has become one of the principal causes of death side-by-side with tuberculosis. We started HCV treatment in 2007. Prior to treatment, all HCV co-infected patients required an HCV genotype testing.
The HCV genotypes distribution in the HIV-infected residents of the Nizhny Novgorod area was studied. We investigated the 366 blood samples taken from 366 patients by polymerase chain reaction method (PCR) using the "AmpliSens-50-R" test-system and the Bio-Rad MyCycler Sample Loading Tray.
HCV genotype 3a predominated in our cohort samples (43.9%) and the remainders were type 1b (33.6%) and type 1a and 2 with low distribution (5.5% and 3.3%, respectively). In 20 samples we have found mixed 1b+3a genotypes; in 30 cases genotypes were not detected.
In the Nizhny Novgorod area, a distribution of HCV genotypes among HIV-infected individuals was observed with a higher prevalence of genotype 3a (43.9%) by comparison with the population of Russia (10.5%). As has been shown in previous research, HCV genotype 3a is a favorable prognostic factor for achieving in most cases a sustained virologic response. Our findings have potential implications for appropriate patient selection for HCV treatment, as individuals carrying this genotype are more likely to respond to therapy.
This article is published under license to BioMed Central Ltd.